Evaluation of the off-label usage of rituximab in a large teaching hospital in New South Wales

被引：9

作者：

Sharma, R.

Koller, L.

Barclay, R.

Liddle, C.

机构：

[1] Westmead Hosp, Dept Clin Pharmacol, Westmead, NSW 2145, Australia

[2] Westmead Hosp, Dept Pharm, Westmead, NSW 2145, Australia

[3] Westmead Childrens Hosp, Dept Pharm, Sydney, NSW, Australia

来源：

INTERNAL MEDICINE JOURNAL | 2007年 / 37卷 / 08期

关键词：

rituximab; off label; cost; drug utilization evaluation;

D O I：

10.1111/j.1445-5994.2007.01406.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A retrospective review of patients receiving rituximab off label in a large teaching hospital was conducted between July 2002 and January 2006. The indication, dosing regimen, efficacy and cost of rituximab were evaluated. Rituximab was prescribed for three clinical indications; acute organ transplant rejection, post-transplant lymphoproliferative disease and autoimmune disease. On average, 600 mg of rituximab was prescribed weekly for 4 weeks, costing the hospital $108 739.37. We suggest an initial approval for a limited number of doses with subsequent approval dependent on improvement in predefined clinical or biochemical end-points. Furthermore, we suggest an Australia-wide central database be established to enable delineation of the optimal dosing schedule, as well as monitoring of clinical outcome.

引用

收藏

页码：569 / 571

页数：3

相关论文

共 12 条

[1] Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma [J].

Anderson, DR ;

GrilloLopez, A ;

Varns, C ;

Chambers, KS ;

Hanna, N .

BIOCHEMICAL SOCIETY TRANSACTIONS, 1997, 25 (02) :705-708

[2] Rituximab as treatment for refractory kidney transplant rejection [J].

Becker, YT ;

Becker, BN ;

Pirsch, JD ;

Sollinger, HW .

AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (06) :996-1001

[3] Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [J].

Clynes, RA ;

Towers, TL ;

Presta, LG ;

Ravetch, JV .

NATURE MEDICINE, 2000, 6 (04) :443-446

[4] Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era [J].

Ghobrial, IM ;

Habermann, TM ;

Ristow, KM ;

Ansell, SM ;

Macon, W ;

Geyer, SM ;

McG egor, CG .

LEUKEMIA & LYMPHOMA, 2005, 46 (02) :191-196

[5] Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases [J].

Gottenberg, JE ;

Guillevin, L ;

Lambotte, O ;

Combe, B ;

Allanore, Y ;

Cantagrel, A ;

Larroche, C ;

Soubrier, M ;

Bouillet, L ;

Dougados, M ;

Fain, O ;

Farge, D ;

Kyndt, X ;

Lortholary, O ;

Masson, C ;

Moura, B ;

Remy, P ;

Thomas, T ;

Wendling, D ;

Anaya, JM ;

Sibilia, J ;

Mariette, X .

ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (06) :913-920

[6] Post-transplant lymphoproliferative disorders [J].

Gottschalk, S ;

Rooney, CM ;

Heslop, HE .

ANNUAL REVIEW OF MEDICINE, 2005, 56 :29-44

[7] Rituximab in the treatment of dermatomyositism - An opel-label pilot study [J].

Levine, TD .

ARTHRITIS AND RHEUMATISM, 2005, 52 (02) :601-607

[8] B cell depletion as a novel treatment for systemic lupus erythematosus - A phase I/II dose-escalation trial of rituximab [J].

Looney, RJ ;

Anolik, JH ;

Campbell, D ;

Felgar, RE ;

Young, F ;

Arend, LJ ;

Sloand, JA ;

Rosenblatt, J ;

Sanz, I .

ARTHRITIS AND RHEUMATISM, 2004, 50 (08) :2580-2589

[9] Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients [J].

Milpied, N ;

Vasseur, B ;

Parquet, N ;

Garnier, JL ;

Antoine, C ;

Quartier, P ;

Carret, AS ;

Bouscary, D ;

Faye, A ;

Bourbigot, B ;

Reguerre, Y ;

Stoppa, AM ;

Bourquard, P ;

de Ligny, BH ;

Dubief, F ;

Mathieu-Boue, A ;

Leblond, V .

ANNALS OF ONCOLOGY, 2000, 11 :113-116

[10]

Montgomery RA, 2004, AM J TRANSPLANT, V4, P258